Excel Therapeutics’ Stock Price Skyrockets ​Amid COVID-19 Resurgence

Excel Therapeutics’⁤ stock price has reached its upper limit, closing at⁤ 7,850 won on⁤ the 3rd, a 22.85% increase‌ from ​the previous trading day.

The surge is attributed to growing expectations of increased demand for specimen‍ transport media for virus ​diagnostic testing, driven by the recent resurgence of ⁢COVID-19.

As the sole producer of‌ the transport media required for transporting samples from individuals tested for COVID-19, the company is poised to‍ benefit from this trend.

Additionally, expectations of⁤ increased exports have contributed to the ⁤stock price hike. Excel Therapeutics has developed Cellker, a cell culture media, in just three years since its establishment, laying the ‌groundwork for mass cell culturing.

Recently, ​the company⁢ signed a contract with a new drug development‌ company to utilize Cellker in‌ a global phase 3 clinical ⁢trial. This⁣ partnership is expected to lead to exports to ⁢30 to 40 countries, resulting in‍ hundreds of billions of won in export performance.

Excel ​Therapeutics, founded in September 2015, specializes in research, development, and production of cell culture media suitable for advanced biopharmaceuticals (CGT).

The⁤ company has ⁢established‍ a cell-customized media development platform technology by incorporating the significance scoring data of media raw material ‍candidate components ⁤by cell type and the know-how of the media development‌ process.

The Ministry of ‍Trade,​ Industry and Energy has recognized the badge⁣ development and manufacturing technology as a key strategic technology in‌ the ⁢field of ‘key cell and material manufacturing⁢ technology ⁣for advanced⁣ biopharmaceutical manufacturing.’